In recent weeks, UiPath announced new agentic AI solutions for healthcare revenue cycle management, achieved the AIUC-1 certification for secure enterprise AI agents, and prepared to report quarterly results on March 11 with investor attention on ARR, revenue guidance, and margins.
Together, these developments highlight UiPath’s push to embed secure, agentic AI deeper into regulated industries such as healthcare, potentially reshaping how enterprises evaluate its automation platform.
Next, we’ll examine how UiPath’s healthcare-focused agentic AI launch could influence the company’s broader investment narrative and long-term positioning.
Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
To own UiPath, I think you need to believe its end to end automation platform can keep attracting enterprise spend even as AI competition intensifies, and that Annualized Recurring Revenue and margins remain the key near term catalysts. The latest healthcare agentic AI launch and AIUC 1 security certification support the product story, but the sharp rise in short interest suggests sentiment around execution and earnings quality is still a meaningful risk.
Among the recent developments, the AIUC 1 certification stands out because it directly addresses security and reliability for enterprise AI agents, an area that matters for regulated adopters like healthcare. For investors watching ARR growth and margin progress, this third party validation of secure automation could help UiPath defend pricing and deepen usage with existing customers, even if macro driven deal delays and SaaS transition headwinds continue to weigh on short term growth.
Yet beneath the product momentum, investors should also be aware that elevated short interest and macro driven deal delays could…
Read the full narrative on UiPath (it’s free!)
UiPath’s narrative projects $1.9 billion revenue and $243.6 million earnings by 2028. This requires 8.6% yearly revenue growth and a $311.1 million earnings increase from -$67.5 million today.
Uncover how UiPath’s forecasts yield a $15.93 fair value, a 33% upside to its current price.
PATH 1-Year Stock Price Chart
Nine fair value estimates from the Simply Wall St Community cluster between US$15.00 and US$21.54, showing how far apart individual views on UiPath can be. As you weigh those perspectives against risks like delayed deal closures caused by the geopolitical backdrop, it is worth considering how different assumptions about ARR resilience and customer budgets may shape very different outlooks for the business.
Explore 9 other fair value estimates on UiPath – why the stock might be worth just $15.00!
Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.
Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PATH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com